3 results
Approved WMOPending
To evaluate the safety and efficacy of ravagalimab vs placebo for the treatment of primary Sjogren's syndrome (pSS) in subjects with moderately to severely active primary Sjogren's syndrome (pSS).
Approved WMOCompleted
The main objective of Study M15-722 is to characterize the efficacy, safety, and tolerability of ravagalimab (ABBV-323) as induction treatment in subjects with moderately to severely active UC.
Approved WMOCompleted
- to determine the recommended phase 2 dose of TG02 in combination with radiotherapy in older patients (>65 years of age) with IDHwt glioblastoma and anaplastic astrocytoma without MGMT promoter methylation- to determine the recommended phase…